Stellaria yunnanensis Franch and its active constituent 20-hydroxyecdysone ameliorate renal failure
Acta Materia Medica · 2026 · 5 (2)
DOI: 10.15212/amm-2026-0003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Materia Medica, 2026. Verfasst von Chao Gu und 12 weiteren Autor:innen. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Chronic renal failure (CRF) is a progressive disease characterized by a sustained loss of kidney function, for which current therapies remain insufficient. Growing evidence closely links the CRF pathogenesis to renal aging; therefore, targeting aging processes might have therapeutic promise. Herein, we implemented a novel strategy to identify potential anti-CRF agents from anti-aging Chinese herbal medicines. Phenotypic screening indicated that the 75% ethanol extract of Stellaria yunnanensis Franch ( JM11002 ) exhibited marked anti-aging activity, by prolonging the lifespan of Caenorhabditis elegans and decreasing the proportion of SA-β-gal-positive senescent MRC-5 cells. Importantly, JM11002 also ameliorated renal dysfunction, inflammation, and fibrosis in both unilateral ischemia-reperfusion injury (UIRI) and unilateral ureteral obstruction (UUO) mouse models. Phytochemical investigation identified 20-hydroxyecdysone ( JM11201 ), a major active component of JM11002 , which recapitulated the renoprotective effects in both the UUO model and unilateral ischemia-reperfusion injury with contralateral nephrectomy (UIRIx) model. Mechanistically, 20-hydroxyecdysone suppressed the TGF-β1/Smad3 signaling pathway and decreased the expression of fibrosis-related proteins in UUO kidneys. In summary, through an aging-intervention strategy, we discovered the renoprotective effect of Stellaria yunnanensis Franch extract and its active component, 20-hydroxyecdysone, two promising candidates for the development of novel CRF therapies.
Zitieren
APA
Gu, C., Wang, J., Zhang, Y., Tu, T., Li, C., Zhang, D., Liu, W., An, F., Xia, C., Wang, M., Li, J., Xu, Y., & Li, X. (2026). Stellaria yunnanensis Franch and its active constituent 20-hydroxyecdysone ameliorate renal failure. Acta Materia Medica, 5(2). https://doi.org/10.15212/amm-2026-0003
Vancouver
Gu C, Wang J, Zhang Y, Tu T, Li C, Zhang D, et al. Stellaria yunnanensis Franch and its active constituent 20-hydroxyecdysone ameliorate renal failure. Acta Materia Medica. 2026;5(2). doi:10.15212/amm-2026-0003
BibTeX
@article{Gu2026,
author = {Gu, Chao and Wang, Jiqun and Zhang, Yishu and Tu, Tianyu and Li, Chao and Zhang, Daoxu and Liu, Wenwen and An, Faliang and Xia, Conglong and Wang, Manjiong and Li, Jian and Xu, Yixiang and Li, Xiaokang},
title = {Stellaria yunnanensis Franch and its active constituent 20-hydroxyecdysone ameliorate renal failure},
journal = {Acta Materia Medica},
year = {2026},
volume = {5},
number = {2},
doi = {10.15212/amm-2026-0003}
}
EUVIMED